Loading page
Loading page
Loading substance route
Methadone has a long and variable half-life. Do not re-dose within several hours, as peak effects and full absorption may be delayed. Clinical OAT typically uses doses of 40-100 mg daily.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Chronic use of methadone is considered extremely addictive with a high potential for abuse, comparable to morphine. It is capable of causing psychological dependence, with cravings developing when regular use is established.
Physical dependence develops with repeated administration through neuroadaptation of opioid receptors. Withdrawal symptoms are reported as significantly more protracted than other opioids due to methadone's long half-life, and include body aches, diarrhea, nausea, anxiety, tremors, tachycardia, sweating, insomnia, fever, and elevated pain sensitivity.
Fatal overdose can cause apnea, circulatory collapse, cardiac arrest, and death, particularly via intravenous administration. Deaths linked to methadone more than quadrupled in the United States between 1999 and 2004, with approximately 82% listed as accidental and most involving combinations with other drugs, especially benzodiazepines. The unpredictable half-life with interindividual variability creates significant overdose risk during initiation or titration.
QT interval prolongation can occur even at therapeutic doses, with risk of potentially fatal torsades de pointes arrhythmia; higher doses (>200 mg/day) and pre-existing cardiac conditions increase this risk significantly.
Serious, life-threatening, or fatal respiratory depression may occur, particularly during dose initiation or titration; the respiratory depressant effects peak later and persist longer than analgesic effects, contributing to iatrogenic overdose risk.
Long-term use is associated with impaired male reproductive function, including decreased testosterone levels, reduced sperm motility and morphology, reduced ejaculate volume, and decreased libido.
Chronic use is associated with significant tooth decay due to dry mouth (xerostomia), which reduces saliva's protective role against decay; behavioral factors such as opioid-related carbohydrate cravings and reduced dental hygiene may contribute.
Injection of oral methadone tablets containing talc filler can cause progressive, irreversible pulmonary hypertension due to particle accumulation in lung vasculature; this risk is specific to intravenous misuse of oral formulations.
Compared to other opioids, methadone has fewer active metabolites and therefore a lower risk of neuropsychiatric toxicity such as delirium at higher doses. However, withdrawal from methadone can cause cognitive symptoms including delirium, auditory and visual hallucinations, paranoia, and delusions.
Methadone is known to lower the seizure threshold. However, due to fewer active metabolites, higher doses are less likely to result in seizures compared to other opioids. Particular caution is warranted during benzodiazepine withdrawal as the combination may potentiate seizure risk.
Methadone was developed in 1937 in Germany by chemists Gustav Ehrhart and Max Bockmühl, working for I.G. Farbenindustrie AG at the Farbwerke Hoechst facility. The research was motivated by Germany's shortage of opium and morphine, creating demand for a synthetic opioid that could be manufactured…
Controlled as a Schedule I substance under the Controlled Drugs and Substances Act. Illegal to sell without authorization and illegal to possess without a valid prescription. Prescriptions can only be obtained from specially licensed physicians, and dispensing is restricted to authorized pharmacies where consumption is typically supervised.
Listed under Anlage III of the Betäubungsmittelgesetz (Narcotics Act), indicating it is a controlled substance that may be prescribed for legitimate medical purposes. Requires a special narcotic prescription form (Betäubungsmittelrezept) for dispensing.
Personal use was decriminalized under Law 30/2000, effective July 2001. Possession of less than one gram is not treated as a criminal offense, though the substance may be seized and the individual referred to a dissuasion commission for potential treatment. Sale and possession of quantities exceeding personal use limits remain criminal offenses subject to imprisonment.
Listed under Verzeichnis A of the Swiss controlled substances regulations. Medicinal use is permitted under appropriate medical supervision for pain management and opioid dependence treatment.
Controlled under the Controlled Substances Act as a Schedule II substance. Illegal to sell without DEA licensure and illegal to possess without a valid prescription. May be prescribed for severe pain management. When used for opioid addiction treatment, methadone can only be dispensed through licensed clinics where patients typically receive liquid formulations under direct observation.
Classified as an Annexe I medication under French pharmaceutical regulations. Illegal to sell without appropriate licensure and illegal to possess without a valid prescription. Prescription methadone is subject to strict controls.
Listed in Tabella I of the official tables of narcotic and psychotropic substances (Tabelle delle sostanze stupefacenti e psicotrope). Unauthorized possession, purchase, or sale is prohibited under national drug legislation.
Classified as a Schedule I controlled substance under Russian federal drug legislation. Production, distribution, and possession are prohibited, including for medical use in opioid substitution therapy programs.
Controlled under the Misuse of Drugs Act 1971 as a Class A substance, carrying the most severe penalties for unauthorized production, supply, or possession. Despite its Class A status, methadone may be legally prescribed for the treatment of opioid dependence.
14 sources cited